Predict your next investment

HEALTHCARE | Biotechnology
rovermed.com

See what CB Insights has to offer

Founded Year

2016

Stage

Acquired | Acquired

Total Raised

$2.2M

About RoverMed BioSciences

RoverMed BioScience develops a drug delivery system that carries medication exclusively into the nuclei of targeted cells no matter where they are in the body.

RoverMed BioSciences Headquarter Location

3051 2nd Street South

Saint Cloud, Minnesota, 56301,

United States

612-437-8836

Latest RoverMed BioSciences News

AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV...

Sep 17, 2019

Expands AAV gene therapy platform from inside the cell for genetic disorders News provided by Share this article RESEARCH TRIANGLE PARK, N.C., Sept. 17, 2019 /PRNewswire/ --  Asklepios BioPharmaceutical, Inc. (AskBio) , a fully integrated Adeno-Associated Virus (AAV) gene therapy platform company focused on providing curative therapeutics for genetic disorders, has acquired the technology assets of RoverMed BioSciences. RoverMed developed nanotechnology cargo delivery of therapeutics into the nucleus of diseased cells without affecting healthy cells. Under the terms of the agreement, AskBio will integrate the company's technology and assume all assets of RoverMed. Consistent with AskBio's focus on meeting the challenges of gene therapy head-on, RoverMed's nanocapsule technology carries large or small molecules, naked DNA and/or viral particles across biological barriers and into the nuclei of the targeted cells, no matter where they are located in the body. This non-viral nanotechnology can potentially achieve unequalled delivery efficiency and precision targeting, as well as repeat administration to reach and treat diseases from inside the cell. "The addition of RoverMed technology provides us with another means for delivering therapeutic molecules, including large or small molecules, to increase stability and specificity and could enable entire new tissues and diseases to be reachable," said Sheila Mikhail, CEO of AskBio. "We continue to explore new technologies and expand therapeutic innovation to ensure that effective gene therapies for genetic disorders can be accessible to patients in need across the globe without limits." AskBio's integrated gene therapy platform includes an expansive capsid library, scaled Pro10™ manufacturing and new delivery methods to accelerate and lower the cost of end-to-end gene therapy processes and support its portfolio of curative therapeutics. About AskBio Founded in 2001, Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held, clinical-stage gene therapy platform company dedicated to improving the lives of children and adults with rare genetic disorders. AskBio's gene therapy platform includes an industry-leading proprietary cell line manufacturing process known as Pro10TM and an extensive AAV capsid library. Based in Research Triangle Park, N.C., the company has generated hundreds of proprietary third-generation gene vectors, several of which have entered clinical testing. An early innovator in the space, the company holds more than 500 patents in areas such as AAV production, chimeric vectors, and self-complementary DNA. AskBio maintains a portfolio of clinical programs across a range of indications, including Pompe, Limb Girdle Muscular Dystrophy, Cystic Fibrosis, Myotonic Muscular Dystrophy, Hemophilia (Chatham Therapeutic/Takeda) and Duchenne Muscular Dystrophy (Bamboo Therapeutics/Pfizer). For more information, visit www.askbio.com . SOURCE AskBio

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RoverMed BioSciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RoverMed BioSciences is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

N

Nanobiotechnology

704 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

RoverMed BioSciences Patents

RoverMed BioSciences has filed 2 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Nanomaterials
  • Nanoparticles
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/22/2019

Molecular biology, Nanoparticles, Transcription factors, MicroRNA, Nanomaterials

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/22/2019

00/00/0000

Grant Date

00/00/0000

Title

Subscribe to see more

Related Topics

Molecular biology, Nanoparticles, Transcription factors, MicroRNA, Nanomaterials

Subscribe to see more

Status

Application

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.